|
 |
| LETTER TO EDITOR |
|
| Year : 2017 | Volume
: 8
| Issue : 3 | Page : 152 |
|
Another feather in the crown of medical safety and ethics in India
Krishnan Vengadaragava Chary
Department of Pharmacology, Saveetha Medical College, Chennai, Tamil Nadu, India
| Date of Web Publication | 13-Jul-2017 |
Correspondence Address:
Krishnan Vengadaragava Chary
Department of Pharmacology, Saveetha Medical College, Chennai - 602 105, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2229-3485.210448
How to cite this article:
Chary KV. Another feather in the crown of medical safety and ethics in India. Perspect Clin Res 2017;8:152 |
Sir,
 Rural Pharmacovigilance | |  |
According to National Survey, nearly 80 million of Indians reside in rural areas, consuming medicines for various diseases and data from them are absolutely essential to make Pharmacovigilance Programme of India (PvPI) penultimate. Indian Council of Medical Research (ICMR) extended this service. ICMR-based rural pharmacovigilance comprises allocating funds to ADR monitoring centers (AMCs) and employing a qualified pharmacist to collect drug safety data of the community in which they are posted and submit it to the nearest AMCs.[1]
| Patient Initiated Medicine Safety Reporting | | |
The hallmark of PvPI, India is the introduction of medicine drug side effects reporting. Undoubtedly, this is successful in western and European nations. The complexity involved in implementing this in our country including people of diverse culture and language, low literacy has been overcome by introducing simple drug side effect reporting form, called 'blue form' against conventional 'red form' used by health-care workers. Direct consumer reporting is further facilitated by availability of forms in eleven Indian vernacular languages including Hindi, Tamil, Telugu, Gujarati, Marathi, etc.[2] This increases autonomy of patients to report adverse effects from over the counter drugs, out of participation in clinical trials and due to conventional medicines. Patient/consumer can report through toll-free number 1800 180 3024 or forms can be E-mailed to pvpi.compat@gmail.com.
Introduction of various measures to increase pharmacovigilance seems to be effective and optimistic. Every medical professionals, paramedical staffs, and patients should be under their responsibility in contributing the drug safety measures failing which the results may not be appreciable.[3]
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Pharmacovigilance Programme of India. National Coordinating Centre, Indian Pharma Oepia Commission. Available from: http://www.ipc.gov.in/PvPI/pv_ievents.html. [Last updated on 2014; Last cited on 2016 Mar 01].  |
| 2. | Kalaiselvan V, Kumar P, Mishra P, Singh GN. System of adverse drug reactions reporting: What, where, how, and whom to report? Indian J Crit Care Med 2015;19:564-6. [ PUBMED] [Full text] |
| 3. | Wilson V, Amma V. Prospects of consumer-initiated adverse drug reaction reporting in cardiovascular pharmacovigilance. J Pract Cardiovasc Sci 2015;1:54-7. [Full text] |
|
